Society of Diabetic Nephropathy Prevention Journal of Nephropharmacology 2345-4202 1 1 2012 01 01 Serum anti-hepatitis B surface antigen in hemodialysis patients 3 5 EN Mahmoud Rafieian-Kopaei Hamid Nasri Journal Article To evaluate the immune response to hepatitis B vaccination in stable hemodialysis (HD) patients, a retro-prospective investigation was conducted on 68 HD patients. Participants were vaccinated against hepatitis B virus with an intramuscular hepatitis B vaccination schedule, 40 micrograms at 0, 1, and 6 months. The serum antibody level against hepatitis B surface antigen (HBs) in HD patients was 35±55. In this study, no significant differences of Anti-HBs antibody between diabetic and non-diabetics or male and female subjects were observed. There were not any significant correlation between antibody against HBs-Ag and serum albumin. There was not significant correlation between anti-HBs antibody and age, proportion of HD, duration of HD or dialysis efficacy. In this study, there was not significant correlation between serum antibody level against hepatitis B surface antigen and some demographic indices of HD patients, however, these findings need to re-test in other centers with more participants.